Nyxoah prices $95M public offering to fund US launch of its Genio sleep apnoea device
What's the deal? Nyxoah (NASDAQ: NYXH), a medical device company focused on sleep apnoea treatment, has priced a $95M underwritten public offering of 55.2 million ordinary shares at $1.72 (€1.48) per share. There are no selling shareholders. Underwriters have a 30-day option to purchase up to 8.3 million additional shares.
The deal is expected to close around June 9, 2026. Nyxoah said it will use net proceeds to fund US commercialisation of its Genio system, R&D and upgrades, international commercialisation, clinical data generation, and general corporate purposes.
The company also plans to draw €13.8M from the second tranche of its European Investment Bank loan in Q2 2026.
Why now? Nyxoah is gearing up for a US commercial launch of its Genio system — a hypoglossal nerve stimulation device for obstructive sleep apnoea. The capital raise suggests the company needs a significant cash infusion to support that rollout, plus ongoing R&D.
The stock has been under pressure, trading near its 52-week low of $2.68, well below its 52-week high of $8.59. Raising capital now, even at a steep discount to recent highs, signals urgency.
What could go wrong? The offering is meaningfully dilutive. Issuing 55.2 million new shares — with the potential for 8.3 million more — will weigh on existing shareholders. The $1.72 offering price sits roughly 40% below the stock's last close of $2.88.
Adding the €13.8M EIB loan draw increases Nyxoah's debt obligations on top of the equity dilution. If the US commercialisation doesn't gain traction quickly, the company may need to raise again.
The signal: Nyxoah's willingness to accept roughly 40% dilution underscores the funding squeeze facing breakout-stage medtech firms bridging the gap between regulatory approval and commercial revenue. The European Investment Bank's continued involvement — via a planned €13.8M loan draw alongside the equity raise — highlights how public-market and government-backed capital are increasingly working in tandem to keep capital-intensive device makers on track through their most expensive phase: a US market launch.
Read more: stocktitan.net
Image: myUpchar, CC BY-SA 4.0, via Wikimedia Commons.
